Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Payables (2021 - 2025)

Historic Payables for Coeptis Therapeutics Holdings (COEP) over the last 5 years, with Q3 2025 value amounting to $883103.0.

  • Coeptis Therapeutics Holdings' Payables fell 6714.86% to $883103.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $883103.0, marking a year-over-year decrease of 6714.86%. This contributed to the annual value of $2.4 million for FY2024, which is 274.27% up from last year.
  • Per Coeptis Therapeutics Holdings' latest filing, its Payables stood at $883103.0 for Q3 2025, which was down 6714.86% from $2.1 million recorded in Q2 2025.
  • Coeptis Therapeutics Holdings' Payables' 5-year high stood at $3.6 million during Q1 2024, with a 5-year trough of $31816.0 in Q1 2021.
  • For the 5-year period, Coeptis Therapeutics Holdings' Payables averaged around $1.7 million, with its median value being $2.0 million (2022).
  • Per our database at Business Quant, Coeptis Therapeutics Holdings' Payables soared by 323615.37% in 2022 and then plummeted by 6714.86% in 2025.
  • Quarter analysis of 5 years shows Coeptis Therapeutics Holdings' Payables stood at $2.6 million in 2021, then decreased by 23.6% to $1.9 million in 2022, then rose by 17.74% to $2.3 million in 2023, then rose by 2.74% to $2.4 million in 2024, then tumbled by 62.54% to $883103.0 in 2025.
  • Its Payables was $883103.0 in Q3 2025, compared to $2.1 million in Q2 2025 and $2.9 million in Q1 2025.